Bafilomycin C1: Benchmark V-ATPase Inhibitor for Autophagy and Lysosomal Acidification Research

Executive Summary: Bafilomycin C1 is a highly selective inhibitor of vacuolar H+-ATPases (V-ATPases), raising the pH of acidic organelles by blocking proton transport (https://www.apexbt.com/bafilomycin-c1.html). This property underpins its pivotal role in autophagy and apoptosis research, especially in high-content phenotypic screening using iPSC-derived models (https://doi.org/10.7554/eLife.68714). The compound is supplied by APExBIO at ≥95% purity, with a molecular weight of 720.9 and stable storage at -20°C. Recent studies confirm its compatibility with multi-modal toxicity assessment platforms and its unique value in interrogating vacuolar ATPase signaling pathways (https://proteinabeads.com/index.php?g=Wap&m=Article&a=detail&id=10813). Bafilomycin C1 remains a gold-standard reagent for mechanistic and translational research in cancer biology and neurodegenerative disease models.

Biological Rationale

Vacuolar H+-ATPases (V-ATPases) are multisubunit proton pumps that acidify intracellular compartments such as lysosomes, endosomes, and Golgi vesicles. This acidification is essential for protein degradation, membrane trafficking, and signal transduction. Disruption of V-ATPase activity impairs autophagic flux, endolysosomal maturation, and can induce apoptotic pathways. In disease models, altered lysosomal acidification is implicated in cancer, neurodegenerative diseases, and metabolic disorders (https://pa-824.com/index.php?g=Wap&m=Article&a=detail&id=15422). Bafilomycin C1 enables precise experimental manipulation of these processes by reversibly inhibiting V-ATPases and altering proton gradients.

Mechanism of Action of Bafilomycin C1

Bafilomycin C1 binds to the V0 domain of V-ATPases, blocking proton translocation across organellar membranes. This raises the intraluminal pH of lysosomes and endosomes, as confirmed by direct pH measurement in live-cell imaging assays (https://e-64d.com/index.php?g=Wap&m=Article&a=detail&id=15736). The compound does not affect plasma membrane ATPases or other major ion pumps at recommended concentrations (typically 10–100 nM in vitro). By elevating lysosomal pH, Bafilomycin C1 impairs the final degradation step in autophagy, allowing researchers to distinguish autophagosome formation from lysosomal fusion or degradation. Its action is rapid (within 30–60 minutes) and reversible upon washout, enabling dynamic studies of acidification-dependent processes.

Evidence & Benchmarks

• Bafilomycin C1 at 100 nM effectively inhibits V-ATPase-mediated acidification, raising lysosomal pH from ~4.5 to ≥6.0 in HEK293T and iPSC-derived cardiomyocytes in under 1 hour (Grafton et al., 2021, DOI).
• In phenotypic screening, Bafilomycin C1 is routinely used as a positive control for lysosomal acidification inhibition and autophagic flux assays (internal summary).
• High-content imaging confirms that Bafilomycin C1 blocks LC3-II turnover, distinguishing autophagosome accumulation from lysosomal degradation defects (Grafton et al., 2021, DOI).
• Bafilomycin C1 does not induce off-target cytotoxicity at concentrations ≤100 nM in iPSC-derived cell models over 24 hours (Grafton et al., 2021, Table 2).
• Purity ≥95% and solubility in ethanol, methanol, DMSO, and DMF are validated for the APExBIO C4729 kit (product page).

This article extends the mechanistic detail provided by 'Bafilomycin C1: The Gold-Standard V-ATPase Inhibitor for ...' by integrating recent data from deep learning-based phenotypic screens and clarifying best practices for iPSC-derived workflows.

Applications, Limits & Misconceptions

Bafilomycin C1 is utilized in:

• Autophagy flux assays (e.g., LC3-II accumulation, p62/SQSTM1 turnover).
• Lysosomal acidification inhibition and trafficking studies.
• Apoptosis research and membrane transporter/ion channel signaling pathway analysis.
• Phenotypic screening in iPSC-derived cell models and high-content imaging platforms (Grafton et al., 2021).
• Disease modeling in cancer biology and neurodegenerative research.

However, Bafilomycin C1 does not inhibit plasma membrane H+-ATPases, nor is it appropriate for long-term exposure (>24 h), as this may lead to off-target effects. It should not be used to infer direct effects on non-acidic organelles. The compound is not stable in aqueous solution for prolonged periods and should be freshly prepared prior to use (Bafilomycin C1).

Common Pitfalls or Misconceptions

• Bafilomycin C1 is not a general cytotoxic agent at ≤100 nM but may cause toxicity at higher concentrations or with prolonged exposure.
• It does not inhibit mitochondrial or plasma membrane ATPases; its action is specific to V-ATPases.
• Bafilomycin C1 will not block pH-dependent processes in non-acidic compartments.
• It is unsuitable for in vivo studies due to poor bioavailability and metabolic instability.
• Stock solutions should not be stored long-term; always use freshly prepared aliquots.

For additional troubleshooting, this article updates the practical recommendations found in 'Strategic V-ATPase Inhibition with Bafilomycin C1: Mechan...' by providing validated concentration ranges and dynamic assay guidance for iPSC-derived and cancer models.

Workflow Integration & Parameters

Bafilomycin C1 is supplied as a powder with a molecular weight of 720.9 and chemical formula C39H60O12. It is readily soluble in ethanol, methanol, DMSO, and dimethyl formamide. For optimal stability, store the compound at -20°C in desiccated conditions. Working solutions (10–100 μM in DMSO) should be diluted into assay buffer immediately before use. Avoid repeated freeze-thaw cycles.

Standard protocols for autophagy flux assays recommend 10–100 nM Bafilomycin C1 for 1–6 hours in cell culture systems, with endpoint readouts including LC3-II immunoblotting, live-cell imaging of lysosomal markers, and high-content screening (https://doi.org/10.7554/eLife.68714). For phenotypic screening in iPSC-derived cardiomyocytes, Bafilomycin C1 is compatible with deep learning-based toxicity detection and can be multiplexed with other pathway inhibitors for mechanistic dissection.

This article clarifies and updates the translational frameworks discussed in 'Harnessing V-ATPase Inhibition: Strategic Insights for Tr...' by detailing integration into high-throughput, AI-enabled protocols.

Conclusion & Outlook

Bafilomycin C1, as supplied by APExBIO (C4729), is a validated, high-purity V-ATPase inhibitor for autophagy, lysosomal acidification, and membrane transporter research. Its selective mechanism and proven compatibility with iPSC-derived and high-content screening workflows position it as a cornerstone reagent for disease modeling and toxicity assessment. Ongoing advances in imaging and AI-powered readouts will further increase the utility of Bafilomycin C1 in de-risking drug discovery and elucidating acidification-dependent pathways.